January 1, 2020Open Access

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis

Key Points

Key points are not available for this paper at this time.

Abstract

Denosumab is associated with a significantly higher risk of developing MRONJ compared to ZA. Nevertheless, no differences were found in its prognoses.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Limones et al. (Wed,) studied this question.

synapsesocial.com/papers/69db23b30d8d6ef495a3d14b https://doi.org/https://doi.org/10.4317/medoral.23324

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity2006 · 2,473 citations
2Osteonecrosis of the jaws induced by anti-RANK ligand therapy2009 · 228 citations
3Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 20162017 · 13,556 citations
4Incidence of bleeding after minor oral surgery in patients on dual antiplatelet therapy: a systematic review and meta-analysis2019 · 33 citations
5Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement2009 · 37,931 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper